MP09-18 CHANGE OF URINARY STEROID METABOLITES IN BPH PATIENTS TREATED WITH DUTASTERIDE

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-surgical Therapy1 Apr 2017MP09-18 CHANGE OF URINARY STEROID METABOLITES IN BPH PATIENTS TREATED WITH DUTASTERIDE Yota Yasumizu, Eiji Kikuchi, Takahiro Maeda, Masanori Hasegawa, Akira Miyajima, and Mototsugu Oya Yota YasumizuYota Yasumizu More articles by this author , Eiji KikuchiEiji Kikuchi More articles by this author , Takahiro MaedaTakahiro Maeda More articles by this author , Masanori HasegawaMasanori Hasegawa More articles by this author , Akira MiyajimaAkira Miyajima More articles by this author , and Mototsugu OyaMototsugu Oya More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.326AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES So far no studies have investigated whether administration of dutasteride (DUT) could affect the steroid metabolite pathway in symptomatic BPH patients. METHODS Urine and blood samples, and clinical parameters such as IPSS, QoL score and prostate volume were prospectively collected before and after 0.5 mg daily DUT administration in 60 symptomatic BPH patients. Among the 60 patients, 25 discontinued DUT after treatment at 12 months and urine samples after the withdrawal of DUT treatment were also prospectively collected. Urine samples were evaluated by urinary steroid profile (USP), which could measure all 63 urinary steroid metabolites at a same time. The USP analysis was determined by gas chromatography/mass spectrometry. We evaluated the pharmacological changes in urinary metabolites in USP and their correlations with clinical parameters in BPH patients treated with DUT. RESULTS The urinary androsterone/etiocholanolone (An/Et) ratio in the sex-steroid pathway was significantly decreased from 1.39 ± 0.62 to 0.02 ± 0.01 (p<0.01). Urinary metabolites in other steroid pathways such as 5αTHF/5βTHF in the glucocorticoid pathway and 5αTHB/βTHB in the mineralocorticoid pathway were also significantly decreased after DUT treatment. In the 25 patients who discontinued DUT treatment, the mean An/Et ratio at baseline before DUT treatment, just before withdrawal of DUT, one month, 3 months, and 6 months after withdrawal of DUT treatment were 0.01, 1.42, 0.02, 0.18, and 1.17, respectively. All other urinary metabolite ratios such 5αTHF/5βTHF and 5αTHB/βTHB were also changed in a similar manner. Prostate volume, IPSS, and QoL score just before withdrawal of DUT treatment (12 months after DUT treatment) were significantly lower than those at baseline before DUT treatment, but these parameters 3 months and 6 months after withdrawal of DUT were not significantly different from those just before withdrawal of DUT treatment. The mean PSA level at baseline before DUT treatment, just before withdrawal of DUT, and 3 months, and 6 months after withdrawal of DUT treatment were 5.6, 2.3, 3.7, and 5.2 ng/ml, respectively. Significant correlation was observed between the recovery rate of PSA level and the recovery rate of An/Et in USP before and 3 months after withdrawal of DUT (ρ=0.61, p<0.01). CONCLUSIONS The urinary 5α/5β metabolites in all steroid pathways were strongly suppressed after daily 0.5 mg DUT administration for one month. The recovery rate of PSA after withdrawal of DUT treatment might reflect the recovery rate of 5α/5β steroid metabolites. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e107 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Yota Yasumizu More articles by this author Eiji Kikuchi More articles by this author Takahiro Maeda More articles by this author Masanori Hasegawa More articles by this author Akira Miyajima More articles by this author Mototsugu Oya More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...